The Experts below are selected from a list of 15 Experts worldwide ranked by ideXlab platform
Karen Flores Rosario - One of the best experts on this subject based on the ideXlab platform.
-
Acute Kidney Injury in Heart Failure Revisited—The Ameliorating Impact of “Decongestive Diuresis” on Renal Dysfunction in Type 1 Acute Cardiorenal Syndrome: Accelerated Rising Pro B Naturetic Peptide Is a Predictor of Good Renal Prognosis
Journal of Clinical Medicine, 2017Co-Authors: Macaulay Onuigbo, Nneoma Agbasi, Mohan Sengodan, Karen Flores RosarioAbstract:There is mounting evidence that Forward Heart Failure as manifested by low cardiac output alone does not define the degree of renal dysfunction in cardiorenal syndrome. As a result, the term “congestive renal Failure” was coined in 2012 by Ross to depict the role of renal venous hypertension in type 1 acute cardiorenal syndrome. If so, aggressive decongestive therapies, either through mechanical ultrafiltration with dialysis machines or pharmacologic ultrafiltration with potent diuretics, would lead to improved cardio and renal outcomes. Nevertheless, as recently as 2012, a review of this literature had concluded that a renal venous hypertension-directed approach using diuretics to manage cardio-renal syndrome was yet to be fully investigated. We, in this review, with three consecutive case series, describe our experience with pharmacologic decongestive diuresis in this paradigm of care and argue for studies of such therapeutic interventions in the management of cardiorenal syndrome. Finally, based on our observations in the Renal Unit, Mayo Clinic Health System, in Northwestern Wisconsin, we have hypothesized that patients with cardiorenal syndrome presenting with accelerated rising Pro B Naturetic Peptide levels appear to represent a group that would have good cardio- and renal-outcomes with such decongestive pharmacologic therapies.
Aaron L. Baggish - One of the best experts on this subject based on the ideXlab platform.
-
Assessment of Heart Failure: Invasive and Non-invasive Methods
Hypertrophic Cardiomyopathy, 2014Co-Authors: Michael A. Fifer, Aaron L. BaggishAbstract:The symptoms of hypertrophic cardiomyopathy (HCM) result from a combination of high filling pressures (“backward” Heart Failure) and low cardiac output (“Forward” Heart Failure). The mainstay of noninvasive testing in symptomatic patients with HCM is transthoracic echocardiography. The detection of concomitant coronary artery disease (CAD) as a cause of symptoms may be difficult by clinical assessment and exercise testing; cardiac computerized tomographic angiography (CTA) has emerged as perhaps the most useful noninvasive test for the assessment of potentially ischemic symptoms due to CAD. Cardiac catheterization is useful for documenting right-sided pressures and cardiac output; determining whether a left ventricular outflow tract (or midcavity) gradient is present at rest or with provocation; separating aortic valvular from subvalvular and supravalvular gradients; determining whether CAD is present; and excluding other pathologic causes of left ventricular thickening. Cardiopulmonary exercise testing provides quantification of functional capacity and distinguishes between cardiac and pulmonary contributions to symptoms.
Macaulay Onuigbo - One of the best experts on this subject based on the ideXlab platform.
-
Acute Kidney Injury in Heart Failure Revisited—The Ameliorating Impact of “Decongestive Diuresis” on Renal Dysfunction in Type 1 Acute Cardiorenal Syndrome: Accelerated Rising Pro B Naturetic Peptide Is a Predictor of Good Renal Prognosis
Journal of Clinical Medicine, 2017Co-Authors: Macaulay Onuigbo, Nneoma Agbasi, Mohan Sengodan, Karen Flores RosarioAbstract:There is mounting evidence that Forward Heart Failure as manifested by low cardiac output alone does not define the degree of renal dysfunction in cardiorenal syndrome. As a result, the term “congestive renal Failure” was coined in 2012 by Ross to depict the role of renal venous hypertension in type 1 acute cardiorenal syndrome. If so, aggressive decongestive therapies, either through mechanical ultrafiltration with dialysis machines or pharmacologic ultrafiltration with potent diuretics, would lead to improved cardio and renal outcomes. Nevertheless, as recently as 2012, a review of this literature had concluded that a renal venous hypertension-directed approach using diuretics to manage cardio-renal syndrome was yet to be fully investigated. We, in this review, with three consecutive case series, describe our experience with pharmacologic decongestive diuresis in this paradigm of care and argue for studies of such therapeutic interventions in the management of cardiorenal syndrome. Finally, based on our observations in the Renal Unit, Mayo Clinic Health System, in Northwestern Wisconsin, we have hypothesized that patients with cardiorenal syndrome presenting with accelerated rising Pro B Naturetic Peptide levels appear to represent a group that would have good cardio- and renal-outcomes with such decongestive pharmacologic therapies.
Nneoma Agbasi - One of the best experts on this subject based on the ideXlab platform.
-
Acute Kidney Injury in Heart Failure Revisited—The Ameliorating Impact of “Decongestive Diuresis” on Renal Dysfunction in Type 1 Acute Cardiorenal Syndrome: Accelerated Rising Pro B Naturetic Peptide Is a Predictor of Good Renal Prognosis
Journal of Clinical Medicine, 2017Co-Authors: Macaulay Onuigbo, Nneoma Agbasi, Mohan Sengodan, Karen Flores RosarioAbstract:There is mounting evidence that Forward Heart Failure as manifested by low cardiac output alone does not define the degree of renal dysfunction in cardiorenal syndrome. As a result, the term “congestive renal Failure” was coined in 2012 by Ross to depict the role of renal venous hypertension in type 1 acute cardiorenal syndrome. If so, aggressive decongestive therapies, either through mechanical ultrafiltration with dialysis machines or pharmacologic ultrafiltration with potent diuretics, would lead to improved cardio and renal outcomes. Nevertheless, as recently as 2012, a review of this literature had concluded that a renal venous hypertension-directed approach using diuretics to manage cardio-renal syndrome was yet to be fully investigated. We, in this review, with three consecutive case series, describe our experience with pharmacologic decongestive diuresis in this paradigm of care and argue for studies of such therapeutic interventions in the management of cardiorenal syndrome. Finally, based on our observations in the Renal Unit, Mayo Clinic Health System, in Northwestern Wisconsin, we have hypothesized that patients with cardiorenal syndrome presenting with accelerated rising Pro B Naturetic Peptide levels appear to represent a group that would have good cardio- and renal-outcomes with such decongestive pharmacologic therapies.
Mohan Sengodan - One of the best experts on this subject based on the ideXlab platform.
-
Acute Kidney Injury in Heart Failure Revisited—The Ameliorating Impact of “Decongestive Diuresis” on Renal Dysfunction in Type 1 Acute Cardiorenal Syndrome: Accelerated Rising Pro B Naturetic Peptide Is a Predictor of Good Renal Prognosis
Journal of Clinical Medicine, 2017Co-Authors: Macaulay Onuigbo, Nneoma Agbasi, Mohan Sengodan, Karen Flores RosarioAbstract:There is mounting evidence that Forward Heart Failure as manifested by low cardiac output alone does not define the degree of renal dysfunction in cardiorenal syndrome. As a result, the term “congestive renal Failure” was coined in 2012 by Ross to depict the role of renal venous hypertension in type 1 acute cardiorenal syndrome. If so, aggressive decongestive therapies, either through mechanical ultrafiltration with dialysis machines or pharmacologic ultrafiltration with potent diuretics, would lead to improved cardio and renal outcomes. Nevertheless, as recently as 2012, a review of this literature had concluded that a renal venous hypertension-directed approach using diuretics to manage cardio-renal syndrome was yet to be fully investigated. We, in this review, with three consecutive case series, describe our experience with pharmacologic decongestive diuresis in this paradigm of care and argue for studies of such therapeutic interventions in the management of cardiorenal syndrome. Finally, based on our observations in the Renal Unit, Mayo Clinic Health System, in Northwestern Wisconsin, we have hypothesized that patients with cardiorenal syndrome presenting with accelerated rising Pro B Naturetic Peptide levels appear to represent a group that would have good cardio- and renal-outcomes with such decongestive pharmacologic therapies.